CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells

The prognosis of many patients with chemotherapy-refractory or multiply relapsed CD30(+) non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) still remains poor, and novel therapeutic approaches are warranted to address this unmet clinical need. In light of this consideration, we designed and pre-cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Guercio, Marika, Orlando, Domenico, Di Cecca, Stefano, Sinibaldi, Matilde, Boffa, Iolanda, Caruso, Simona, Abbaszadeh, Zeinab, Camera, Antonio, Cembrola, Biancamaria, Bovetti, Katia, Manni, Simona, Caruana, Ignazio, Ciccone, Roselia, Del Bufalo, Francesca, Merli, Pietro, Vinti, Luciana, Girardi, Katia, Ruggeri, Annalisa, De Stefanis, Cristiano, Pezzullo, Marco, Giorda, Ezio, Scarsella, Marco, De Vito, Rita, Barresi, Sabina, Ciolfi, Andrea, Tartaglia, Marco, Moretta, Lorenzo, Locatelli, Franco, Quintarelli, Concetta, De Angelis, Biagio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018158/
https://www.ncbi.nlm.nih.gov/pubmed/32381575
http://dx.doi.org/10.3324/haematol.2019.231183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018158/
https://www.ncbi.nlm.nih.gov/pubmed/32381575
http://dx.doi.org/10.3324/haematol.2019.231183

Ejemplares similares